Dr. Molly E. Steed, PharmD

School of Pharmacy - Pharmacy Practice
Clinical Assistant Professor
Primary office:
913-588-5325

Room Wescoe, 6009D
The University of Kansas School of Pharmacy
3901 Rainbow Blvd, MS 4047
Kansas City, KS 66160


Clinical Assistant Professor Molly Steed earned a Pharm.D. in 2005 from the University of Wisconsin School of Pharmacy. She continued her training at the University of Kentucky, where she completed a PGY1 Pharmacy Practice Residency, a PGY2 Infectious Diseases Pharmacy Residency and The Scholarship of Teaching and Learning Certificate Program.

Courses and Rotations

  • Pharmacy Practice 648
  • Pharmocotherapy 3
  • Clinical Infectious Diseases Clerkship Elective
  • Research Infectious Diseases Clerkship Elective

Professional Leadership and Service

  • American College of Clinical Pharmacy
  • National Lipid Association
  • American Association of Colleges of Pharmacy
  • American College of Clinical Pharmacy (College of Pharmacy Liaison)

Specializations

  • Examination of antimicrobial pharmacokinetics and pharmacodynamics utilizing in vitro models and therapeutic treatment options for multi-drug resistant organisms.

Recent Awards and Honors

  • ASM Infectious Diseases Fellow Travel Grant, 51st Interscience Conference on Antimicrobial Agents (September, 2011)
  • ECCMID Fellow Registration Grant, 20th European Congress of Clinical Microbiology and Infectious Diseases (April, 2010)
  • Wyeth ICAAC Infectious Diseases Fellow Grant, 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (September, 2009)

Selected Publications

  • Steed ME, Werth BJ, Ireland CE, Rybak MJ.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.  Antimicrob Agents Chemother.  2012;56:5709-14.
  • Steed ME, Vidaillac C, Rybak MJ. Evaluation of telavancin activity vs. vancomycin and daptomycin against daptomycin non-susceptible Staphylococcus aureus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.  Antimicrob Agents Chemother.  2012;56:955-59.
  • Steed ME, Vidaillac C, Rose WE, Winterfield P, Kaatz G, Rybak MJ.  Characterizing vancomycin resistant Enterococcus faecium strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.  Antimicrob Agents Chemother.  2011;55:4748-4754.
  • Steed ME, Vidaillac C, Rybak MJ.  Evaluation of ceftaroline activity versus daptomycin against daptomycin non-susceptible methicillin resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.  Antimicrob Agents Chemother.  2011;55:3522-3526.
  • Steed ME, Rybak MJCeftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.  Pharmacotherapy.  2010;30:375-389.

Selected Presentations

  • Steed ME.  Systemic triazole antifungal agents.  Invited Presentation at the Missouri Society of Health System Pharmacists & Kansas Council of Health System Pharmacists 2012 Annual Meeting.  Kansas City, MO.  April 2012.
  • Steed ME.  Superbugs! Clinical Controversies in the Management of Multiple-Drug Resistant Bacteria:  MRSA Bacteremia with Elevated Vancomycin MIC’s – Is Daptomycin really Superior?  Invited presentation at the American Society of Health-System Pharmacists 2012 Midyear Clinical Meeting.  Las Vegas, NV.  December 2012.
  • Steed ME, Werth BJ, Ireland CE, Rybak MJ.  Evaluation of the novel combination of high dose daptomycin (HD-DAP) plus trimethoprim/sulfamethoxazole (TMP/SMX) against daptomycin non-susceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) using an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model of simulated endocardial vegetations (SEVs).  Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.  San Francisco, CA.  September 2012.
  • Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ.  Evaluation of ceftaroline’s activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with varying susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.  Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.  Chicago, IL.  September 2011. 
  • Steed ME, Avery L, Woodruff A, Rybak MJ.  Evaluation of daptomycin plus trimenthoprim-sulfamethoxazole or rifampin activity in an in vitro pharmacokinetic/pharmacodynamic model against VISA and daptomycin non-susceptible Staphylococcus aureus isolates from osteomyelitis cases.  Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.  Chicago, IL.  September 2011. 
  • Steed ME, Vidaillac C, Rybak MJ.  Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin non-susceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.  Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.  Chicago, IL.  September 2011.
  • Steed ME, Vidaillac C, Rybak MJ.  Evaluation of ceftaroline activity vs. daptomycin against daptomycin non-susceptible methiciliin resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.  Oral presentation at the 21st European Congress of Clinical Microbiology and Infectious Diseases/ 27th International Congress of Chemotherapy.  Milan, Italy.  May 2011.

Events
KU Today
2nd among all schools of pharmacy in National Institutes of Health funding
Brings more than $20 million in external funding into the state each year
7 of 19 cancer drugs formulated through the National Cancer Institute were developed at the KU School of Pharmacy
3,000 free flu shots given to needy Kansans during the past 5 years
4,000 living alumni, 63 percent of them living and working in Kansas
KU pharmacists practice in 95 of Kansas’ 105 counties
20th among public schools of pharmacy.
—U.S. News & World Report
$20.2 million NIH research grant earned by Distinguished Professor Jeff Aubé was 2nd largest in Kansas history
100 percent placement after graduation for KU Pharm.D. students
Established in 1885 as the 1st professional program at KU